Ryzneuta Injection
NDC Package 72893-016-02

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Ryzneuta (efbemalenograstim alfa-vuxw) injection is rYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.Limitations of UseRYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. This formulation utilizes a injection delivery system. Marketed by Acrotech Biopharma Inc, this product is identified by NDC 72893-016 and is authorized under FDA application BLA761134.

Identification & Billing

NDC Package Code
72893-016-02
Package Description
1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE
Product Code
72893-016
11-Digit Billing Format
72893001602
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 2670662 - efbemalenograstim alfa-vuxw 20 MG in 1 ML Prefilled Syringe
  • RxCUI: 2670662 - 1 ML efbemalenograstim alfa-vuxw 20 MG/ML Prefilled Syringe
  • RxCUI: 2670662 - efbemalenograstim alfa-vuxw 20 MG per 1 ML Prefilled Syringe
  • RxCUI: 2670669 - Ryzneuta 20 MG in 1 ML Prefilled Syringe
  • RxCUI: 2670669 - 1 ML efbemalenograstim alfa-vuxw 20 MG/ML Prefilled Syringe [Ryzneuta]

Clinical Specifications

Proprietary Name
Ryzneuta
Non-Proprietary Name
Efbemalenograstim Alfa-vuxw
Substance Name
Efbemalenograstim Alfa
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
EFBEMALENOGRASTIM ALFA 20 mg/mL
Pharmacologic Class
Usage Information
RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.Limitations of UseRYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Regulatory & Marketing

Labeler Name
Acrotech Biopharma Inc
Product Type
Human Prescription Drug
FDA Application #
BLA761134
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
11-23-2023
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72893-016-02 identifies a specific commercial package of 1 syringe in 1 carton / 1 ml in 1 syringe of Ryzneuta, a human prescription drug labeled by Acrotech Biopharma Inc. This injection is formulated for subcutaneous use and contains efbemalenograstim alfa as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Acrotech Biopharma Inc on November 23, 2023. The current certification is valid through December 31, 2027.

How is this Acrotech Biopharma Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72893001602. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72893-016-02
11-Digit CMS (5-4-2)
72893-0016-02

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.